CELL INTELLIGENCE · 肿瘤细胞治疗研究

抗 CD22/CD19 CAR-T 细胞疗法 CAR-T2219.1 在成人和儿童复发/难治性 B-ALL 中的 I/II 期试验

A Phase I/II Trial of Anti-CD22/CD19 CAR-T Cell Therapy, CART2219.1, in Adult and Pediatric Relapsed/Refractory B-ALL.

CD84 在急性髓系白血病不同疾病阶段和白血病亚群中的表达

CD84 Expression Across Disease Stages and Leukemic Subpopulations in Acute Myeloid Leukemia.

结合现有的临床前和临床证据，这些发现支持继续评估靶向CD84的免疫疗法，包括CAR T细胞疗法，在AML中的应用。

儿童慢性活动性 EB 病毒感染按优势感染淋巴细胞亚群管理后的长期结局

Long-term outcomes of chronic active Epstein-Barr virus infection in childhood after dominantly infected lymphocyte subpopulation management.

EBV 感染淋巴细胞谱分析指导 CAEBV 的长期无 HCT 控制。CD4+T 细胞型 CAEBV 需及时而非择期进行 HCT，以防疾病进展和转化。

CAR-T 细胞治疗在儿童急性淋巴细胞白血病中的应用：面向普通儿科医师的综述

CART-Cell Therapy in Pediatric Acute Lymphoblastic Leukemia: A Review for General Pediatricians.

CD19-CAR-T 细胞在儿童、青少年及年轻成人 B 细胞急性淋巴细胞白血病患者脑脊液中的长期存续

CD19-CAR T cells persist long-term in the cerebrospinal fluid of pediatric, adolescent and young adult patients with B-cell acute lymphoblastic leukem

Tisagenlecleucel 用于年轻急性淋巴细胞白血病患者移植后复发：欧洲真实世界结局决定因素

Tisagenlecleucel for post-transplant relapse in young acute lymphoblastic leukemia patients: European real-world determinants of outcome.

白血病中纤维-微生物群-屏障轴的治疗生态学：韧性、免疫恢复与药物微生物组学

Therapeutic ecology of the fiber-microbiota-barrier axis in leukemia: resilience, immune recovery and pharmacomicrobiomics.

白细胞单采时外周原始细胞是儿童和年轻成人接受 tisagenlecleucel 后生存的风险因素

Peripheral Blasts at Apheresis as a Risk Factor for Survival following Tisagenlecleucel in Children and Young Adults.

Tisagenlecleucel 在复发/难治性 ALL 儿童及年轻成人患者中的长期临床结局

Long-Term Clinical Outcomes of Tisagenlecleucel in Pediatric and Young Adult Patients With Relapsed/Refractory ALL.

KMT2A 重排成人 B 细胞急性淋巴细胞白血病的治疗进展

Therapeutic Advances in Adult B-cell Acute Lymphoblastic Leukemia with KMT2A Rearrangements.